Current Research Studies

Evaluates the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)  Mark Bieniarz, Principal Investigator

Evaluates whether the drug canakinumab reduces further events in patients who have had previous Myocardial Infarctions.   Robert Orchard, MD Principal Investigator

Compares the On-X valve on low dose anticoagulation to concomitant groups of On-X valves receiving standard coumadin/aspirin therapy and to also drive FDA objective performance criteria (OPC).  Paul Levy, MD Principal Investigator

Evaluates the effectiveness and safety of a Newly Devised Drug in Patients with Chronic Heart Failure.  Robert Orchard, MD Principal Investigator

Compares different heart tests in identifying heart disease in patients with symptoms, and to attempt to reduce future problems with the heart. Brendan Cavanaugh, MD Principal Investigator

Post approval study of a Paclitaxel-Eluting Coronary Stent System.  Robert E. Federici, MD Principal Investigator

ABSORB: A stent study for patients requiring intervention.  Robert Federici, MD Principal Investigator

ANALYZE-ST: Tests the accurary of the ST monitoring feature on Implantable Cardioverter Defibrillator (ICD).  Sean Mazer, MD Principal Investigator

RE-ALIGN: Tests the efficacy and safety of the drug Dabigatran after heart valve replacement. Paul Levy, MD Principal Investigator

WARFARIN: Attempts to reduce the adverse effects of this popular blood thinner by looking at genetic variations